[go: up one dir, main page]

AR054822A1 - Emulsion inmuno adyuvante - Google Patents

Emulsion inmuno adyuvante

Info

Publication number
AR054822A1
AR054822A1 ARP060102917A ARP060102917A AR054822A1 AR 054822 A1 AR054822 A1 AR 054822A1 AR P060102917 A ARP060102917 A AR P060102917A AR P060102917 A ARP060102917 A AR P060102917A AR 054822 A1 AR054822 A1 AR 054822A1
Authority
AR
Argentina
Prior art keywords
emulsion
oil
admission
immunogenic composition
water
Prior art date
Application number
ARP060102917A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR054822A1 publication Critical patent/AR054822A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)

Abstract

Emulsion coadyuvante de aceite en agua, que comprende por lo menos: escualeno; un solvente acuoso; un surfactante no ionico a base de éter de polioxietilenalquilo; un surfactante no ionico hidrofobo; donde la emulsion es termorreversible, y donde el 90% de la cantidad en volumen de las gotas de aceite tiene un tamano inferior a 200 nm. Además se relaciona con un proceso para la preparacion de una composicion inmunogena, de acuerdo con el cual se mezcla por lo menos un antígeno de vacuna con una emulsion de aceite en agua, donde la emulsion de aceite en agua se obtiene por medio de un proceso de inversion de fase por variacion de temperatura. Uso, composicion inmunogénica.
ARP060102917A 2005-07-07 2006-07-06 Emulsion inmuno adyuvante AR054822A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0508310 2005-08-04

Publications (1)

Publication Number Publication Date
AR054822A1 true AR054822A1 (es) 2007-07-18

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102917A AR054822A1 (es) 2005-07-07 2006-07-06 Emulsion inmuno adyuvante

Country Status (24)

Country Link
EP (2) EP2080522B1 (es)
JP (1) JP5300475B2 (es)
KR (1) KR101328638B1 (es)
CN (1) CN101217977B (es)
AR (1) AR054822A1 (es)
AT (1) ATE424845T1 (es)
AU (1) AU2006268466B2 (es)
BR (1) BRPI0614053A2 (es)
CA (1) CA2613732C (es)
CY (2) CY1108994T1 (es)
DE (1) DE602006005671D1 (es)
DK (2) DK2080522T3 (es)
EA (1) EA012376B1 (es)
ES (2) ES2390104T3 (es)
IL (1) IL187967A0 (es)
MX (1) MX2007016412A (es)
NO (1) NO336369B1 (es)
NZ (1) NZ564173A (es)
PL (2) PL2080522T3 (es)
PT (2) PT2080522E (es)
SG (1) SG163584A1 (es)
SI (2) SI2080522T1 (es)
TN (1) TNSN08001A1 (es)
WO (1) WO2007006939A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200701787A1 (ru) 2005-03-23 2008-08-29 Глаксосмитклайн Байолоджикалс С.А. Иммунная композиция, способ ее изготовления, ее применение и способ вакцинации
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567978A (en) * 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US9562075B2 (en) 2007-05-31 2017-02-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
US20110150926A1 (en) 2008-08-01 2011-06-23 Mohammed Alsharifi Influenza vaccines
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
DK2400951T3 (en) 2009-02-25 2018-12-03 Mayne Pharma Llc TOPICAL FOAM COMPOSITION
PH12012500694A1 (en) 2009-10-09 2012-10-29 Cbio Ltd Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
EP2817286B1 (en) 2012-03-23 2018-06-06 Pitney Pharmaceuticals Pty Limited Kinase inhibitors for the treatment of cancer
CA2875683A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
MY197723A (en) 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US9790176B2 (en) 2012-08-06 2017-10-17 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mTOR pathway related diseases
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
US11369666B2 (en) 2012-12-17 2022-06-28 Newsouth Innovations Pty Limited Treatment of diseases involving mucin
AU2013370932B2 (en) 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP3016968B1 (en) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105267963A (zh) * 2014-06-18 2016-01-27 潘皓 纳米乳疫苗辅剂的制备方法
CN107073350B (zh) 2014-07-21 2019-11-15 赛诺菲巴斯德股份公司 用于产生液滴的液体给送装置
CN107427569B (zh) 2015-03-26 2022-12-30 Gpn疫苗有限公司 链球菌疫苗
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
CN108697782A (zh) * 2016-03-23 2018-10-23 英特维特国际股份有限公司 针对pcv2病毒和猪肺炎支原体感染的组合疫苗
US12065482B2 (en) 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
TW202219057A (zh) 2020-08-24 2022-05-16 美商賽諾菲巴斯德公司 針對ＳＡＲＳ－ＣｏＶ－２感染的新型疫苗
AU2024228998A1 (en) 2023-03-02 2025-10-16 Sanofi Pasteur Compositions for use in treatment of chlamydia
CN118662475A (zh) * 2023-03-16 2024-09-20 清华大学 固体化自微乳疫苗的制备与应用
AU2024267861A1 (en) 2023-05-05 2026-01-08 Sanofi Pasteur Inc. Compositions for use in treatment of acne
CN116531514A (zh) * 2023-05-29 2023-08-04 大连理工大学 一种烷基糖苷表面活性剂在铝佐剂冻干中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
JP2607712B2 (ja) 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
AU764969B2 (en) * 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
ATE444735T1 (de) * 2001-03-21 2009-10-15 Madash Llc Thermisch reversible wasser-in-öl-in-wasser- emulsionen
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
PL1904099T3 (pl) 2009-08-31
JP2009500382A (ja) 2009-01-08
PL2080522T3 (pl) 2012-11-30
NO336369B1 (no) 2015-08-10
JP5300475B2 (ja) 2013-09-25
DK2080522T3 (da) 2012-10-08
SI1904099T1 (sl) 2009-08-31
AU2006268466A1 (en) 2007-01-18
CA2613732C (en) 2013-12-10
WO2007006939A3 (fr) 2007-04-05
DE602006005671D1 (en) 2009-04-23
ATE424845T1 (de) 2009-03-15
EA012376B1 (ru) 2009-10-30
ES2390104T3 (es) 2012-11-06
CN101217977B (zh) 2013-03-06
CY1113414T1 (el) 2016-06-22
KR101328638B1 (ko) 2013-11-27
EP2080522A1 (fr) 2009-07-22
CY1108994T1 (el) 2014-07-02
AU2006268466B2 (en) 2011-11-10
SI2080522T1 (sl) 2012-10-30
SG163584A1 (en) 2010-08-30
PT1904099E (pt) 2009-05-29
CA2613732A1 (en) 2007-01-18
EP2080522B1 (fr) 2012-07-04
PT2080522E (pt) 2012-10-01
NO20080585L (no) 2008-03-26
NZ564173A (en) 2010-10-29
TNSN08001A1 (fr) 2009-07-14
EA200800271A1 (ru) 2008-04-28
IL187967A0 (en) 2008-03-20
EP1904099B1 (fr) 2009-03-11
DK1904099T3 (da) 2009-06-08
CN101217977A (zh) 2008-07-09
MX2007016412A (es) 2008-03-07
ES2322102T3 (es) 2009-06-16
EP1904099A2 (fr) 2008-04-02
WO2007006939A2 (fr) 2007-01-18
BRPI0614053A2 (pt) 2011-03-09
KR20080030076A (ko) 2008-04-03

Similar Documents

Publication Publication Date Title
AR054822A1 (es) Emulsion inmuno adyuvante
CL2004000691A1 (es) Emulsion submicrometrica de aceite en agua de utilidad como adyuvante de vacuna que comprende un aceite, un tensoactivo y un componente acuoso y tamano medio de gota inferior a 1 um; procedimiento para preparar la emulsio; composicion de vacuna que c
EA200801250A1 (ru) Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа
ES2585810T3 (es) Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
AR067087A1 (es) Composicion de vacuna y metodo para elaborarla
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
HRP20080235T3 (hr) Formulacija vakcine koja sadrži emulziju ulje-u-vodi
BR0314102A (pt) Uso de tensoativos para solubilizar sólidos não-solúveis em água em bebidas
AR047254A1 (es) Composicion de acido alquilxilen sulfonico sub-neutralizado para procesos para la recuperacion asistida de petroleo.
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
CY1112572T1 (el) Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
EA200900350A1 (ru) Вакцина, содержащая адъювант в виде эмульсии "масло в воде"
NO20023829L (no) Proteosom influensavaksine
NO20025629L (no) Formulering
AR061906A1 (es) Limpiador de baja espuma
RU2012145455A (ru) Эмульсии, используемые в напитках
JP2008524584A5 (es)
GB2534038A (en) Oil-in-water stable, emulsified spacer fluids
AR112507A1 (es) Mejoradores de la solubilidad a base de alcohol alílico para formulaciones tensioactivas acuosa para recuperación de petróleo mejorada
ES2539792T3 (es) Vehículo en forma de una emulsión aceite-en-agua destinado principalmente a una utilización oftálmica o dermocosmética
AR098326A1 (es) Tensioactivos de copolímero para uso en fluidos de fondo de pozo
EA200800509A1 (ru) Пониженная интерференция между маслосодержащими адъювантами и антигенами, содержащими поверхностно-активные вещества
UY39202A (es) Composición de prometrina en forma de micro emulsión
FR2971399B1 (fr) Emulsion huile dans eau ou eau dans l'huile a base d'huiles vegetales en tant qu'adjuvant phytopharmaceutique.
AR113503A1 (es) Auxiliares de flujo de retorno en microemulsión para usos en yacimientos de petróleo

Legal Events

Date Code Title Description
FB Suspension of granting procedure